Status:
COMPLETED
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)
Eligibility Criteria
Inclusion
- Diagnosed as essential hypertension -
Exclusion
- Patients with secondary hypertension or suspected of having secondary hypertension.
- Patients suspected of having malignant hypertension
- Patients with any serious diseases or symptoms
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00246584
Start Date
October 1 2004
Last Update
July 28 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Basel, Switzerland